Display Settings:

Format

Send to:

Choose Destination

    Expert Opin Drug Saf. 2008 Jul;7(4):411-9.

    Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus.

    Aringer M, Smolen JS.

    University Clinical Center Carl Gustav Carus, Technical University of Dresden, Division of Rheumatology, Department of Medicine III, Fetscherstrasse 74, 01307 Dresden, Germany. martin.aringer@uniklinikum-dresden.de

    BACKGROUND: There is still unmet medical need in the therapy of severe organ manifestations of patients with systemic lupus erythematosus (SLE). Therapeutic agents targeting pro-inflammatory cytokines may be an interesting option. OBJECTIVE: To review available data on the efficacy and safety of tumour necrosis factor (TNF) blockade in SLE. METHODS: A review of the literature was conducted. RESULTS/CONCLUSIONS: Open-label experience suggests that TNF blockade is effective in SLE patients with arthritis, nephritis and skin disease. In particular, nephritis may remain in long-term remission after just four infusions of infliximab administered. Despite the induction of lupus-specific autoantibodies, short-term therapy with infliximab in combination with azathioprine appears feasible and relatively safe. The data call for controlled clinical trials, at least one of which has been initiated.

    PMID: 18613805 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Azathioprine (Azasan®, Imuran®)

      Azathioprine is used with other medications to prevent rejection of kidney transplants. It is also used to treat severe rheumatoid arthritis (a condition in which the body attacks its own joints, causing pain and swellin...